Dr. Zhao works in research administration and in basic and clinical urology and andrology. His earlier work includes investigating the developmental mechanisms of non-obstructive azoospermia (Nature Communications, 2020), developing lipid-regulation therapies for testicular aging (Nature Aging, 2024; Aging Cell, 2026), and mapping the single-cell microenvironment and spatial multi-omics landscape of the corpus cavernosum (Nature Communications, 2022; Cell Reports, 2024).

He holds seven national invention patents, four of which have been translated into applied outcomes. His honors include the 2023 World Chinese Urological Society Rising Star Award, the 2023 Chinese Medical Science and Technology Award, and the 2025 Guangdong Provincial Teaching Achievement Award. He serves on the young editorial board of Med Research and reviews for journals including The Lancet.

Professor Tang serves on national and regional professional committees spanning andrology, sexual medicine, urology, integrative medicine, and reproductive medicine, and chairs the Andrology Branch of the Zhuhai Medical Association. He is also a peer reviewer for the National Natural Science Foundation of China and an evaluation expert for the National Science and Technology Awards platform. He has led five General Program projects funded by the National Natural Science Foundation of China and five provincial or ministerial research projects, received four provincial, ministerial, or municipal research awards, and published more than 60 papers as first or corresponding author, including more than 40 SCI-indexed articles.

His long-term clinical and basic research focuses on male sexual dysfunction, male infertility, and prostate disease, with particular emphasis on the molecular mechanisms of testicular tumors and erectile dysfunction. His group uses multi-omics approaches to study regulatory mechanisms in reproductive aging, has integrated multiple data sources to build a cross-species, life-course single-cell transcriptomic atlas of the human and mouse testis, and has collaborated with several institutions to establish Male Health Atlas, a multi-omics data portal for the male genitourinary system. Over the past five years, the team has published 25 papers on the causes, diagnosis, treatment, and prognosis of male reproductive diseases in journals including Cell Reports, Nature Communications, Nature Aging, Research, Aging Cell, Communications Biology, Andrology, and Asian Journal of Andrology.

Professor Dai graduated from Hengyang Medical College in 1991, received a master’s degree from the University of South China in 2001, and earned a doctorate from Xiangya School of Medicine, Central South University, in 2004. From January 2008 to 2010, he was a visiting scholar and assistant researcher at the University of Texas Medical School at Houston. His long-term research examines male sexual dysfunction and fibrosis after kidney injury. He applies contemporary minimally invasive microsurgical and molecular-biology techniques to challenging clinical questions in male urologic health.

He has led one National Natural Science Foundation of China project, one Wu Jieping Medical Foundation project, and several provincial natural-science projects; participated in multiple international collaborations; and received four provincial or municipal research awards. He has published more than 60 papers in journals including Cell Reports, Nature Medicine, Andrology, Journal of Clinical Investigation, and Sexual Medicine. He also holds committee appointments in robotic urologic surgery, male fertility regulation, kidney cancer, urologic oncology, geriatric andrology, and the Zhuhai Medical Association.

Li has published more than 30 papers as first or corresponding author in journals including Phytomedicine, International Journal of Biological Macromolecules, and Molecular Cancer, with a cumulative impact factor above 170. Li has led or contributed to several provincial, ministerial, municipal, and departmental projects; served as deputy editor and lead translator for two academic books; and contributed to five approved national invention patents. This work was selected for an electronic poster presentation at CUA2025, the 32nd Annual Meeting of the Chinese Urological Association.

The main research focus is multi-omics integration and computational biology in urologic tumors and male reproductive health, with particular attention to tumor-microenvironment remodeling, metabolic reprogramming, and epigenetic regulation.

Li serves as a guest editor for a special issue of BMC Women’s Health and as a reviewer for SCI-indexed journals including Journal of Translational Medicine, Cell Death & Disease, and International Journal of Molecular Medicine.

Wang has published several SCI-indexed papers as first or principal author in journals including Science China Life Sciences, Pharmacology & Therapeutics, and Biochimica et Biophysica Acta - Molecular Basis of Disease, with a cumulative impact factor of 33. Wang has led or participated in several national and provincial undergraduate innovation and entrepreneurship training projects, and has received more than ten national, provincial, and ministerial honors. These include a national silver award in the National Undergraduate Life Sciences Competition, a national bronze award in the National Undergraduate Basic Medical Innovation Research and Experimental Design Forum, and first prize in the Shandong Provincial Challenge Cup competition. The related work was selected for presentation at the International Conference on Tumor Pharmacology and Precision Cancer Therapy and Young Scholars Taishan Academic Conference, as well as the annual meeting of the Shandong Anatomical Society. Wang also served as the Shandong provincial lead for the national Chinese Residents’ Psychology and Behavior Survey project.

The main research focus is basic and translational research in urologic andrology and male reproductive health, particularly the regulatory mechanisms of testicular aging and Leydig-cell function, abnormal lipid deposition, and organelle interactions.